Flammeemoji!!!
Ser med et halvt øye, men virker å være litt nytt i presentasjonen. Håper de legger den ut etterpå
Det var dette Victor (med et smil om munnen) nevnte på webcasten i november som en utfordring.
Presentasjon fra 3:10:00
https://www.redeye.se/events/966283/redeye-theme-cell-therapy?tab=schedule
rømmer de ansatte skuta allerede?
Her er det flere innfallsvinkler som kan være aktuelt, og som kan tilpasses for ulike indikasjoner. Om man må vinkle det negativt og kalle det et problem, så er det hvertfall et luksus-problem. Og det er garantert at det ikke blir søvnløse netter av dette. Ikke for meg hvertfall
Hørte på redeye nå og EDW sier tydelig at veien til markedet er betydelig nedkortet i den ruten som er valgt. Det er mye penger spart. Og det betyr alt!
Så, prising utifra kreft-selskap og kost på vei til markedet, det blir ikke riktig. Det kan bety vanvittig fine avtaler.
offensiv og god E.W på Redeye i dag
Greitt nok elendig track record på gjengen, men no fikk eg trua på snarlig suksess.Få Kina pengane i Mars/April gode nyheter mtp ip/forskning
Mandagens salg var i stor grad preget av Atlas og en privatperson som har ligget blant topp 5. Dersom man antar at begge skal tømme seg helt, så hadde de totalt 225 000 aksjer per mandag. Kjøperlisten var lang og har ekstremt mye småkjøp. Det kommer nok fra Finansavisen artikkelen.
etter i dag er vel begge nesten tomme vil eg tru
Er nok fryktelig nærme tomt ja! 
Nesten like god og solid eierstruktur i CRNA som i Ultimo 
Er jo litt relevant dette da, eller ? Sånn for å sette ting litt i perspektiv.
Ikke voldsomt store studier heller som for øyeblikket rekrutterer innen dette feltet:
Column1
Study List:
Study 1:
NCT Number: NCT06049082
Title: A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
Acronym: Serpentine-1
Status: Recruiting
Study Results: No Results Available
Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Drug: KB408 (Nebulization)
Outcome Measures: To evaluate safety and tolerability of KB408 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in vital signs, ECG, spirometry, and clinical laboratory test results|To assess the effect of KB408 on serum alpha-1 antitrypsin (AAT) concentration|To assess the effect of KB408 on plasma neutrophil elastase (NE) concentration|To evaluate the effect of KB408 on AAT concentration in the lung|To evaluate the effect of KB408 on NE concentration in the lung
Sponsor/Collaborators: Krystal Biotech, Inc.
Gender: All
Age: 18 Years to 70 Years (Adult, Older Adult)
Phases: Phase 1
Enrollment: 12
** Fun**ded Bys: Industry
Study Type: Interventional
Study Designs: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
Other IDs: KB408-01
Start Date: February 2024
Primary Completion Date: June 2025
Completion Date: June 2025
First Posted: September 21, 2023
Results First Posted:
Last Update Posted: February 6, 2024
Locations: Medical University of South Carolina, Charleston, South Carolina, United States
Study Documents:
Study 2:
NCT Number: NCT04722887
Title: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
Acronym:
Status: Recruiting
Study Results: No Results Available
Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Biological: Alpha-1 15%|Biological: Liquid Alpha1-Proteinase Inhibitor (Human)
Outcome Measures: Number of Participants With Adverse Events (AEs)|Number of Participants With Suspected Adverse Drug Reactions (ADRs)|Number of Participants With Infusion Site Reactions|Number of Participants With Serious Adverse Events (SAEs)|Number of Participants With AEs and SAEs Leading to Discontinuation|Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Number of Participants With Clinically Significant Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1)|Change from Baseline in Forced Vital Capacity (FVC)|Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)|Immunogenicity: Number of Participants With Alpha1-PI Antibodies
Sponsor/Collaborators: Grifols Therapeutics LLC
Gender: All
Age: 18 Years to 80 Years (Adult, Older Adult)
Phases: Phase 1|Phase 2
Enrollment: 16
Funded Bys: Industry
Study Type: Interventional
Study Designs: Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
Other IDs: GC2008
Start Date: August 13, 2021
Primary Completion Date: March 14, 2025
Completion Date: March 14, 2025
First Posted: January 25, 2021
Results First Posted:
Last Update Posted: January 16, 2024
Locations: Dignity Health-St. Joseph’s Hospital & Medical Center, Phoenix, Arizona, United States|UCLA Medical Center, Los Angeles, California, United States|George Washington University, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Southeastern Research Center, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Medical University of South Carolina - Children’s Hospital, Charleston, South Carolina, United States|Renovatio Clinical, The Woodlands, Texas, United States
Study Documents:
Study 3:
NCT Number: NCT06186492
Title: A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
Acronym: RestorAATion-1
Status: Recruiting
Study Results: No Results Available
Conditions: Alpha-1 Antitrypsin Deficiency
Interventions: Drug: WVE-006
Outcome Measures: The proportion of participants with adverse events|Single Ascending Dose - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast)|Single Ascending Dose - Maximum concentration of WVE-006 in plasma (Cmax)|Multiple Ascending Doses - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast)|Multiple Ascending Doses - Maximum concentration of WVE-006 in plasma (Cmax)
Sponsor/Collaborators: Wave Life Sciences Ltd.
Gender: All
Age: 18 Years to 65 Years (Adult, Older Adult)
Phases: Phase 1
Enrollment: 56
Funded Bys: Industry
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
Other IDs: WVE-006-001
Start Date: November 14, 2023
Primary Completion Date: December 2024
Completion Date: December 2024
First Posted: January 2, 2024
Results First Posted:
Last Update Posted: January 2, 2024
Locations: Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, Wales, United Kingdom
Study Documents:
Study 4:
NCT Number: NCT05727800
Title: A Phase 1, First-in-human Study of VX-668
Acronym:
Status: Recruiting
Study Results: No Results Available
Conditions: Alpha-1 Antitrypsin Deficiency
Interventions: Drug: VX-668|Drug: Placebo
Outcome Measures: Part A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part A and B: Maximum Observed Plasma Concentration (Cmax) of VX-668|Part A and B: Area Under the Concentration Versus Time Curve (AUC) of VX-668|Part A and B: Urine Concentration of VX-668
Sponsor/Collaborators: Vertex Pharmaceuticals Incorporated
Gender: All
Age: 18 Years to 55 Years (Adult)
Phases: Phase 1
Enrollment: 114
** Fun**ded Bys: Industry
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Other IDs: VX22-668-001
Start Date: February 8, 2023
Primary Completion Date: September 12, 2023
Completion Date: January 2024
First Posted: February 14, 2023
Results First Posted:
Last Update Posted: November 18, 2023
Locations: Celerion - Tempe, Tempe, Arizona, United States|University of Florida, Gainesville, Florida, United States|Central Florida Pulmonary Group, P.A., Orlando, Florida, United States|ICON Lenexa, Lenexa, Kansas, United States|ICON Salt Lake City, Salt Lake City, Utah, United States
Study Documents:
URL: A Phase 1, First-in-human Study of VX-668 - Full Text View - ClinicalTrials.gov
Study 5:
NCT Number: NCT05579431
Title: A Phase 1, First-in-human Study of VX-634
Acronym:
Status: Recruiting
Study Results: No Results Available
Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Drug: VX-634|Drug: Placebo
Outcome Measures: Part A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part A and B: Maximum Observed Plasma Concentration (Cmax) of VX-634|Part A and B: Area Under the Concentration Versus Time Curve (AUC) of VX-634|Part A and B: Urine Concentration of VX-634
Sponsor/Collaborators: Vertex Pharmaceuticals Incorporated
Gender: All
Age: 18 Years to 55 Years (Adult)
Phases: Phase 1
Enrollment: 114
** Fun**ded Bys: Industry
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Other IDs: VX22-634-001
Start Date: October 13, 2022
Primary Completion Date: May 24, 2023
Completion Date: June 2024
First Posted: October 13, 2022
Results First Posted:
Last Update Posted: October 2, 2023
Locations: Celerion - Tempe, Tempe, Arizona, United States|University of Florida, Gainesville, Florida, United States|Central Florida Pulmonary Group, P.A., Orlando, Florida, United States|ICON Lenexa, Lenexa, Kansas, United States|ICON Salt Lake City, Salt Lake City, Utah, United States
Study Documents:
URL: A Phase 1, First-in-human Study of VX-634 - Full Text View - ClinicalTrials.gov
Study 6:
NCT Number: NCT05315921
Title: Study of OsrhAAT or Placebo in Healthy Volunteers
Acronym:
Status: Recruiting
Study Results: No Results Available
Conditions: Emphysema Secondary to Congenital AATD
Interventions: Drug: OsrhAAT 1 mg/kg IV|Drug: OsrhAAT 3 mg/kg IV|Drug: OsrhAAT 10 mg/kg IV|Drug: OsrhAAT 20 mg/kg IV|Drug: OsrhAAT 40 mg/kg IV|Drug: OsrhAAT 60 mg/kg IV
Outcome Measures: Safety and tolerability: Incidence of adverse events (AEs), serious adverse events (SAEs), and infusion site reactions
Sponsor/Collaborators: Healthgen Biotechnology Corp.
Gender: All
Age: 18 Years to 55 Years (Adult)
Phases: Phase 1
Enrollment: 48
** Fun**ded Bys: Industry
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other
Other IDs: HY1003-2021-P1
Start Date: March 22, 2022
Primary Completion Date: March 31, 2023
Completion Date: June 30, 2023
First Posted: April 7, 2022
Results First Posted:
Last Update Posted: December 12, 2022
Locations: Altasciences, Cypress, California, United States
Study Documents:
URL: Study of OsrhAAT or Placebo in Healthy Volunteers - Full Text View - ClinicalTrials.gov
Study 7:
NCT Number: NCT05891158
Title: A Study About Fazirsiran in People With and Without Liver Problems
Acronym:
Status: Recruiting
Study Results: No Results Available
Conditions: Hepatic Impairment
Interventions: Drug: Fazirsiran
Outcome Measures: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Fazirsiran|Area Under the Plasma Concentration-time Curve from Time 0 to Infinity (AUC0-inf) for Fazirsiran|Maximum Observed Plasma Concentration (Cmax) for Fazirsiran|Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Clinically Significant Abnormal Values for Laboratory Parameters|Number of Participants With Clinically Significant Abnormal Values for Vital Signs Parameters|Number of Participants With Clinically Significant Abnormal Values for Electrocardiogram (ECG) Parameters|Number of Participants With Clinically Significant Abnormal Values for Pulmonary Function Parameters|Number of Participants With Injection Site Reaction|Amount of Drug Excreted in Urine From Time 0 to Time 24 hours (Ae0-24hrs) for Fazirsiran|Amount of Drug Excreted in Urine From Time 0 to Time 6 hours (Ae0-6hrs) for Fazirsiran|Amount of Drug Excreted in Urine From Time 6 to Time 24 hours (Ae6-24h) for Fazirsiran|Percent of Recovered Drug in Urine Compared With the Dose (%Dose [u])|Renal Clearance (CLr) for Fazirsiran|Absolute Change in Serum Alpha-1 Antitrypsin (AAT) at Nadir|Percentage Change in Serum AAT at Nadir|Absolute Change in Serum AAT|Percentage Change in Serum AAT
Sponsor/Collaborators: Takeda
Gender: All
Age: 18 Years to 85 Years (Adult, Older Adult)
Phases: Phase 1
Enrollment: 41
Funded Bys: Industry
Study Type: Interventional
Study Designs: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
Other IDs: TAK-999-1001|2023-503735-17
Start Date: October 5, 2023
Primary Completion Date: April 15, 2025
Completion Date: April 15, 2025
First Posted: June 6, 2023
Results First Posted:
Last Update Posted: December 1, 2023
Locations: CRU Hungary Kft, Kistarcsa, Hungary|Summit Clinical Research s.r.o., Bratislava, Slovakia|Summit Clinical Research s.r.o., Malacky, Slovakia|Summit Clinical Research s.r.o., Nove Zamky, Slovakia
Study Documents:
Ingen som trur på E.W og gjengen tydeligvis,aksjer blir pøst ut desverre ikkje berre Atlas
Har forståelse for at folk mister troen,Edv bare prater og prater,beviser ingen ting,eneste han bryr seg om,er å suge tilseg mest mulig penger.
Skal tro om musa får noe søvn der den lyser opp i hverdagen ? Ikke bare bare å være med i musestudier. Håper maten smaker, og at rullehjulet er godt smurt.
